MYRICX Trademark

Trademark Overview

On Wednesday, August 6, 2025, a trademark application was filed for MYRICX with the United States Patent and Trademark Office. The USPTO has given the MYRICX trademark a serial number of 79444386. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Saturday, February 28, 2026. This trademark is owned by Myricx Pharma Limited. The MYRICX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treat...

Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development, testing and commercialisation of pharmaceuticals and biotechnological preparations (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases (term considered too vague by the International Bureau pursuant to Rul...
myricx

General Information

Serial Number79444386
Word MarkMYRICX
Filing DateWednesday, August 6, 2025
Status638 - NEW APPLICATION - ASSIGNED TO EXAMINER
Status DateSaturday, February 28, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging.
Goods and ServicesScientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development, testing and commercialisation of pharmaceuticals and biotechnological preparations (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); consultancy, advisory and information services relating to the aforesaid services.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 26, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, February 26, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMyricx Pharma Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Thursday, February 26, 2026SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, February 27, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 27, 2026APPLICATION FILING RECEIPT MAILED
Saturday, February 28, 2026ASSIGNED TO EXAMINER

Related Keywords

myricx diseases diagnosis human treatment preparations biotechnological adcs conjugates antibody scientific